Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

ASH 2024

Lymphoma

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

ASH 2024

Lymphoma

REALBiTE: Real-world analysis of epcoritamab and glofitamab in patients with R/R LBCL

Skin Cancer

Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy

Eur J Cancer

Egeler M, Lai-Kwon J, Tissier R, Fraterman I, Kuijpers A, Van Houdt W, Wilgenhof S, Rao A, Sandhu S, Lee R, Eriksson H, van Leeuwen M, de Ligt K, van Akkooi A, van de Poll-Franse L

doi: 10.1016/j.ejca.2024.113601

Lung, Respiratory and Thoracic Cancer

Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion-positive NSCLC: Real-world outcomes from the GuardantINFORM database

J Thorac Oncol

Parikh K, Dimou A, Leventakos K, Mansfield AS, Shanshal M, Wan Y, Lin HM, Vincent S, Elliott J, Bonta IR

doi: 10.1016/j.jtho.2024.07.009

SPECIAL REPORT

Lymphoma

Real-World Comparison of YESCARTA^® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

Skin Cancer

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Eur J Cancer

Amaral T, Nanz L, Higuita LMS, Ascierto P, Berking C, Couselo EM, Donia M, Dummer R, Gutzmer R, Haushild A, Jalving M, Lee R, Lorigan P, Marquez-Rodas I, Michelin O, Nathan P, Robert C, Schadendorf D, Sobczuk P, Flatz L, Leiter U, Garbe C

doi: 10.1016/j.ejca.2024.115160

Breast Cancer

Correlation Between Disease-Free Survival Endpoints and Overall Survival in Elderly Patients with Early-Stage HER2-Negative Breast Cancer: A SEER-Medicare Analysis

Adv Ther

Earla JR, Kurian AW, Kponee-Shovein K, Mahendran M, Song Y, Hua Q, Hilts A, Sun Y, Hirshfield KM, Robson M, Mejia JA

doi: 10.1007/s12325-024-03074-7

ASH 2024

Lymphoma

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Lung, Respiratory and Thoracic Cancer

Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort

ESMO Open

Thomas QD, Quantin X, Lemercier P, Chouaid C, Schneider S, Filleron T, Remon-Masip J, Perol M, Debieuvre D, Audigier-Valette C, Justeau G, Loeb A, Hiret S, Clement-Duchene C, Dansin E, Stancu A, Pichon E, Bosquet L, Girard N, Du Rusquec P

doi: 10.1016/j.esmoop.2024.103473

Related content

Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement

REALBiTE: Real-world analysis of epcoritamab and glofitamab in patients with R/R LBCL

Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy

Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion-positive NSCLC: Real-world outcomes from the GuardantINFORM database

Real-World Comparison of YESCARTA® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Correlation Between Disease-Free Survival Endpoints and Overall Survival in Elderly Patients with Early-Stage HER2-Negative Breast Cancer: A SEER-Medicare Analysis

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

Real-World Comparison of YESCARTA^® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL